Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors

Table 1

Most common adverse events in mTOR-I-treated renal transplant recipients.

Adverse events	Rate of occurrence (%)	References
Pulmonary toxicity	2–11	[20, 21, 24, 33]
Hematopoietic adverse effects
Anemia	13–58	[6, 36, 44–47, 50, 56, 57, 70, 72, 135, 147]
Leukopenia	5–39	[6, 45, 46, 56, 66, 117, 121, 147]
Thrombocytopenia	4–45	[6, 45–47, 56, 66, 70, 117, 118, 121, 122, 147]
Metabolic disorders
Hyperlipidemia	8–87	[6, 45–47, 57, 66, 70–72, 115, 117, 118, 121, 135, 147]
Posttransplantation diabetes	3–33	[56, 70, 72, 78, 80, 115, 121, 138, 147]
Hypophosphatemia	15–20	[45, 46, 57]
Lymphedema	<5	[99–102]
Cardiovascular disease	1–6	[80, 100, 117, 122, 124, 128]
Hypertension	8–58	[46, 57, 70, 72, 115, 117, 121, 122, 135]
Cutaneous adverse effects
Acne, folliculitis	9–25	[6, 57, 70, 116–118, 135, 147]
Stomatitis and mucous membrane disorders	9–64	[6, 118, 138, 147]
Edema	2–70	[6, 56, 57, 70, 121, 122, 135, 147]
Nail and hair pathologies	74	[116]
Gonadal complications	<5	[123–126]
Surgical wound complication	2–20	[56, 70, 72, 133–136]
Infections	2–60	[6, 72, 117, 122, 136]
Gastrointestinal complication	2–51	[6, 46, 47, 56, 57, 70, 72, 117, 118, 121, 135, 147]